原发性自发性与口服抗凝药相关脑出血中的抗血小板治疗
本研究汇总回顾性队列与前瞻性单中心数据,分析抗血小板治疗对原发性自发性脑出血、维生素K拮抗剂(VKA)相关脑出血及非VKA口服抗凝药相关脑出血的血肿特征与结局的影响。共分析3545例患者,发现VKA相关脑出血中抗血小板治疗与更差功能结局、更高死亡率及更大血肿体积相关,而原发性自发性及非VKA相关脑出血中未见显著差异。
要点
- VKA相关脑出血中,抗血小板治疗组功能结局(mRS 0-3)比例低于无抗血小板组(23.8% vs 31.9%,P=0.030)。
- VKA相关脑出血中,抗血小板治疗组死亡率高于无抗血小板组(51.0% vs 40.4%,P=0.009)。
- VKA相关脑出血中,抗血小板治疗组血肿体积大于无抗血小板组(21.9 mL vs 15.7 mL,P=0.005)。
核心结论
- 抗血小板治疗不影响原发性自发性脑出血患者的血肿特征和结局。
- 在VKA相关脑出血中,抗血小板治疗与更大血肿体积和更差功能结局相关,推测由叠加的抗止血效应所致。
- 抗凝与抗血小板联合治疗应仔细评估并限制在尽可能短的时间范围内。
研究设计与样本
- 汇总回顾性队列研究和前瞻性单中心研究的数据。
- 共筛选3580例脑出血患者,其中3545例有抗血小板治疗信息并纳入分析。
- 采用倾向性评分匹配和logistic回归分析评估单用或双联抗血小板治疗与血肿体积的关联。
主要发现
- 原发性自发性脑出血中346例(32.4%)、VKA相关脑出血中260例(11.4%)、非VKA口服抗凝药相关脑出血中30例(16.0%)接受抗血小板治疗,这些患者合并症更严重。
- 倾向性评分匹配后,VKA相关脑出血中抗血小板治疗组功能结局(改良Rankin量表评分0-3)为48/202(23.8%),无抗血小板组为187/587(31.9%),P=0.030;死亡率分别为103/202(51.0%)和237/587(40.4%),P=0.009。
- 原发性自发性脑出血和非VKA口服抗凝药相关脑出血中,抗血小板治疗组与无抗血小板组无显著差异。
- VKA相关脑出血中,抗血小板治疗组血肿体积为21.9(7.4-61.4)mL,无抗血小板组为15.7(5.7-44.5)mL,P=0.005。
- 多变量回归分析显示抗血小板治疗与更大脑出血体积相关(比值比1.80 [1.20-2.70],P=0.005),在双联抗血小板治疗和超治疗水平抗凝患者中更为明显。
临床怎么用
- 作者认为,抗凝与抗血小板联合治疗应仔细评估并限制在尽可能短的时间范围内。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- This study determined the influence of concomitant antiplatelet therapy (APT) on hematoma characteristics and outcome in primary spontaneous intracerebral hemorrhage (ICH), vitamin K antagonist (VKA)- and non-VKA oral anticoagulant-associated ICH. Methods- Data of retrospective cohort studies and a prospective single-center study were pooled. Functional outcome, mortality, and radiological characteristics were defined as primary and secondary outcomes. Propensity score matching and logistic regression analyses were performed to determine the association between single or dual APT and hematoma volume. Results- A total of 3580 patients with ICH were screened, of whom 3545 with information on APT were analyzed. Three hundred forty-six (32.4%) patients in primary spontaneous ICH, 260 (11.4%) in VKA-ICH, and 30 (16.0%) in non-VKA oral anticoagulant-associated ICH were on APT, and these patients had more severe comorbidities. After propensity score matching VKA-ICH patients on APT presented with less favorable functional outcome (modified Rankin Scale score, 0-3; APT, 48/202 [23.8%] versus no APT, 187/587 [31.9%]; P=0.030) and higher mortality (APT, 103/202 [51.0%] versus no APT, 237/587 [40.4%]; P=0.009), whereas no significant differences were present in primary spontaneous ICH and non-VKA oral anticoagulant-associated ICH. In VKA-ICH, hematoma volume was significantly larger in patients with APT (21.9 [7.4-61.4] versus 15.7 [5.7-44.5] mL; P=0.005). Multivariable regression analysis revealed an association of APT and larger ICH volumes (odds ratio, 1.80 [1.20-2.70]; P=0.005), which was more pronounced in dual APT and supratherapeutically anticoagulated patients. Conclusions- APT does not affect ICH characteristics and outcome in primary spontaneous ICH patients; however, it is associated with larger ICH volume and worse functional outcome in VKA-ICH, presumably by additive antihemostatic effects. Combination of anticoagulation and APT should, therefore, be diligently evaluated and restricted to the shortest possible time frame.
引用
- Sprügel MI, Kuramatsu JB, Gerner ST, et al. Antiplatelet Therapy in Primary Spontaneous and Oral Anticoagulation-Associated Intracerebral Hemorrhage. Stroke. 2018. PMID: 30355188. doi:10.1161/STROKEAHA.118.021614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。